Q-omics provides the consensus-scored CTAGE10P profile across patient tissues and cancer cell-line models. CTAGE10P expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, CTAGE10P is differentially expressed in 7, with the highest sampling consensus in UCEC. Additionally, CTAGE10P RNA expression shows 7,131 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight UCEC, and TGCT as cancer lineages where CTAGE10P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CTAGE10P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CTAGE10P survival associations across molecular data types. CTAGE10P RNA expression shows survival associations in the most cancer types (24). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CTAGE10P RNA expression–survival associations across cancer types. High CTAGE10P expression shows unfavorable associations in UCEC, UCS and UVM, but favorable associations in KIRP, BRCA and COAD. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for CTAGE10P RNA expression.
This table summarizes CTAGE10P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for CTAGE10P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CTAGE10P shows lower tumor expression in THCA and higher tumor expression in UCEC, BRCA, COAD, KIRP and READ. The UCEC box plot shows higher CTAGE10P RNA expression in tumor versus normal tissue (log2 FC = +0.037, t-test p = .010).
This table shows molecular features associated with CTAGE10P in patient tissues and cancer cell lines. In patient samples, CTAGE10P shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, CTAGE10P RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT.
